Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 853-858

  Wei, Xiaoxiong ^a,b,f   Dai, Renke ^c   Zhai, Suoping ^a,b,g   Thummel, Kenneth E ^d   Friedman, Fred K ^c   Vestal, Robert E ^a,b,e,h  

^a St Luke's Mountain States Tumor Institute   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; LIDOCAINE; MEXILETINE; TOCAINIDE;

ANTIARRHYTHMIC ACTIVITY; CATALYSIS; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; HEART VENTRICLE ARRHYTHMIA; IMMUNOBLOTTING; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; KINETICS; LIDOCAINE; MEXILETINE; MODELS, MOLECULAR; OXIDOREDUCTASES; TOCAINIDE;

EID: 0032954379     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Beckett AH and Chidomere EC (1977) The identification and analysis of mexiletine and its metabolic products in man. J Pharm Pharmacol 29:281-285.
2. Burke MD and Mayer RT (1974) Ethoxyresorufin: Direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 2:583-588.
3. Burke M, Thompson S, Elcombe CR, Halpert J, Haaparanta T and Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazonea and homologues: A series of substrates to distinguish between induced cytochrome P-450. Biochem Pharmacol 34:3337-3345.
4. Burke MD, Thompson S, Weaver RJ, Wolf CR and Mayer RT (1994) Cytochrome P-450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936.
5. Dai R, Zhai S, Wei X, Pincus MR, Vestal RE and Friedman FK (1998) Inhibition of human cytochrome P-450 1A2 by flavones: A molecular modeling study. J Prot Chem 17:643-650.
6. Hurwitz A, Vacek JL, Botteron GW, Sztern MI, Hughes EM and Jayaraj A (1991) Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 50:299-307.
7. Joeres R, Klinker H, Heusler H, Epping J and Richter E (1987) Influence of mexiletine on caffeine elimination. Pharmacol Ther 38:163-169.
8. Keefe DL, Kates RE and Harrison DC (1981) New antiarrhythmic drugs: Their place in therapy. Drugs 22:363-400.
9. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ and Levy RH (1994) Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 47:1969-1979.
10. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
11. Loi CM, Wei X and Vestal RE (1991) Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clin Pharmacol Ther 49:571-580.
12. Loi CM, Wei X, Parker BM, Korrapati MR and Vestal RE (1993) The effect of tocanide on theophylline metabolism. Br J Clin Pharmacol 35:437-440.
13. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
14. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS and Boobis AR (1993) Human hepatic CYP1A1 and CYP1A2 content, determined with specific antipeptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis (Oxford) 14:585-592.
15. cam. J Mol Biol 195:687-700.
16. Sarkar MA, Hunt C, Guzelian PS and Karnes HT (1992) Charaterization of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab Dipos 20:31-37.
17. Sesardic D, Boobis AR, Edwards RJ and Davies DS (1988) A form of cytochrome P-450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarrete smoking. Br J Clin Pharmacol 26:363-372.
18. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH and Miners JO (1994) Caffeine metabolism by human hepatic cytochrome P-450: Contributations of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
19. Towbin H, Staehelin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
20. Weaver RJ, Thompson S, Smith G, Dickens M, Elcombe CR, Mayer RT and Burke MD (1994) A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P-450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochem Pharmacol 47:763-773.
21. Wei X, Loi CM, Schmucker DL and Vestal RE (1995a) Characterization of the independent and combined effects of two inhibitors on oxidative drug metabolism in rat liver microsomes. Biochem Pharmacol 49:1657-1663.
22. Wei X, Loi CM, Jarvi EJ and Vestal RE (1995b) Relative potency of mexiletine, lidocaine and tocainide as inhibitors of rat liver CYP1A1 activity. Drug Metab Dispos 23:1335-1338.
23. Williams DA (1995) pKa values of some drugs and miscellaneous organic acids and bases, in Principles of Medicinal Chemistry, 4th ed (Foye WO ed) p 955, Williams & Wilkins, Baltimore.